VOR Quote, Financials, Valuation and Earnings

Outset Medical, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -60.61%. Vor Biopharma, Inc.'s return on equity of -- beat Outset Medical, Inc.'s return on equity of -81.05%.

Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 238.91%. On the other hand Outset Medical, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 161.11%. Given that Vor Biopharma, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Vor Biopharma, Inc. is more attractive than Outset Medical, Inc..

Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Outset Medical, Inc. has a beta of 2.079, suggesting its more volatile than the S&P 500 by 107.879%.

Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Outset Medical, Inc. pays out -- of its earnings as a dividend.

Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Outset Medical, Inc. quarterly revenues of $29.4M. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Outset Medical, Inc.'s net income of -$17.8M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Outset Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 0.89x for Outset Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of -3135.32%. Vor Biopharma, Inc.'s return on equity of -- beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 238.91%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 75.88%. Given that Vor Biopharma, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Vor Biopharma, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 36.51x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Senti Biosciences, Inc. has a net margin of -- compared to Vor Biopharma, Inc.'s net margin of --. Vor Biopharma, Inc.'s return on equity of -- beat Senti Biosciences, Inc.'s return on equity of -173.17%.

Vor Biopharma, Inc. has a consensus price target of $44.60, signalling upside risk potential of 238.91%. On the other hand Senti Biosciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 1136.16%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..

Vor Biopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Senti Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vor Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vor Biopharma, Inc. pays -- of its earnings as a dividend. Senti Biosciences, Inc. pays out -- of its earnings as a dividend.

Vor Biopharma, Inc. quarterly revenues are --, which are smaller than Senti Biosciences, Inc. quarterly revenues of --. Vor Biopharma, Inc.'s net income of -$812.7M is lower than Senti Biosciences, Inc.'s net income of -$18.1M. Notably, Vor Biopharma, Inc.'s price-to-earnings ratio is -- while Senti Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vor Biopharma, Inc. is -- versus 3.27x for Senti Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.